Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aprea Therapeutics, Inc.

2.40
+0.02501.05%
Post-market: 2.400.00000.00%19:13 EDT
Volume:11.20K
Turnover:26.58K
Market Cap:13.04M
PE:-0.88
High:2.47
Open:2.30
Low:2.30
Close:2.38
Loading ...

Company Profile

Company Name:
Aprea Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
7
Office Location:
3805 Old Easton Road,Doylestown,Pennsylvania,United States
Zip Code:
18902
Fax:
- -
Introduction:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Directors

Name
Position
Christian S. Schade
Chairman
Oren Gilad
Chief Executive Officer and President and Director
Bernd R. Seizinger
Director
Gabriela Gruia
Director
John B. Henneman, III
Director
Marc Duey
Director
Michael Grissinger
Director
Richard Peters
Director
Rifat Pamukcu
Director

Shareholders

Name
Position
Oren Gilad
Chief Executive Officer and President and Director
John P. Hamill
Senior Vice President, Chief Financial Officer and Secretary